Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study

Hiroshi Minaguchi; Tsuguo Uemura; Kazuhiro Shirasu; Akira Sato; Susumu Tsukikawa; Yoshito Ibuki; Hideki Mizunuma; Takeshi Aso; Takao Koyama; Shiro Nozawa; Hiroaki Ohta; Toshiyuki Ikeda; Koji Kusuhara; Kazuhiko Ochiai; Junzo Kato; Toshihiko Kinoshita; Kenichi Tanaka; Yusuke Minagawa; Takumi Kurabayashi; Masao Fukunaga

doi:10.1111/j.1447-0756.1996.tb00976.x

Bone Health · Hormones and Bone

Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study

Minaguchi H, Uemura T, Shirasu K, Sato A, Tsukikawa S, Ibuki Y, Mizunuma H, Aso T, Koyama T, Nozawa S, Ohta H, Ikeda T, Kusuhara K, Ochiai K, Kato J, Kinoshita T, Tanaka K, Minagawa Y, Kurabayashi T, Fukunaga M

Published June 1996 The Journal of Obstetrics and Gynaecology Research, 22(3), 259-265

DOI 10.1111/j.1447-0756.1996.tb00976.x PMID 8840712

Abstract

Objectives

To assess the effects of oral estriol on the bone mineral density (BMD) and bone metabolism in postmenopausal women.

Methods

Seventy-five natural postmenopausal women with a BMD of more than 10% below the peak bone density were treated for 50 weeks with 2 mg/day estriol (E3) cyclically and 0.8 g/day of calcium lactate continuously. BMDs at L2-L4 were measured by dual energy X-ray absorptiometry (DXA).

Results

The BMD increased 1.79% (p < 0.01 vs. pretreatment) after 50 weeks, accompanied with decrease of biochemical markers of bone turnover. With regard to climacteric symptoms, Kupperman's menopausal index improved (p < 0.01 vs. pretreatment) after 5 weeks of treatment. As to the incidence of adverse events genital bleeding was observed in only 8.0% of the subjects. Endometrial histology and cytology showed neither abnormalities nor hyperplasia during and after the treatment.

Conclusions

Estriol prevented postmenopausal bone loss and improved climacteric symptoms effectively with low incidence of genital bleeding.

Topics

Bone Health › Hormones and Bone › Estrogen and Bone · Therapeutics › Hormonal Agents › Estrogen Preparations · Perimenopause and Menopause › Hormone Therapy › Benefits and Risks

Hiroshi Minaguchi, Tsuguo Uemura, Kazuhiro Shirasu, Akira Sato, Susumu Tsukikawa, Yoshito Ibuki, Hideki Mizunuma, Takeshi Aso, Takao Koyama, Shiro Nozawa, Hiroaki Ohta, Toshiyuki Ikeda, Koji Kusuhara, Kazuhiko Ochiai, Junzo Kato, Toshihiko Kinoshita, Kenichi Tanaka, Yusuke Minagawa, Takumi Kurabayashi, Masao Fukunaga

H Minaguchi, T Uemura, K Shirasu, A Sato, S Tsukikawa, Y Ibuki, H Mizunuma, T Aso, T Koyama, S Nozawa, H Ohta, T Ikeda, K Kusuhara, K Ochiai, J Kato, T Kinoshita, K Tanaka, Y Minagawa, T Kurabayashi, M Fukunaga

PMID 8840712 8840712 DOI 10.1111/j.1447-0756.1996.tb00976.x 10.1111/j.1447-0756.1996.tb00976.x Minaguchi et al. 1996, Minaguchi 1996

Keywords

Bone Density/drug Effects, Climacteric/drug Effects, Estriol/pharmacology/therapeutic Use, Female, Humans, Middle Aged, Osteoporosis, Postmenopausal/blood/prevention & Control, Prospective Studies, Estriol

Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study

Abstract

Topics

By this author

Related research

Keywords